Skip to content

News

Comparative immune profiling of acute respiratory distress syndrome patients with or without SARS-CoV2 infection

Comparative immune profiling of acute respiratory distress syndrome patients with or without SARS-CoV2 infection May 21 2021 ScailyteTM and ScaiVisionTM are registered trademarks proprietary to Scailyte AG. Recent News
Read More

Scailyte Quarterly Update, April 2021

Quarterly update on Scailyte's progress towards its mission to save millions of lives.
Read More

VACANCY: Director of Biomarker Discovery

VACANCY: Director of Biomarker Discovery Mar 31 2021 Director of Biomarker Discovery Company description: Scailyte is a globally recognized spin-off from ETH Zürich and pioneer in the field of single-cell
Read More

Scailyte and Geninus announce a strategic partnership to develop a predictive assay for immune-checkpoint inhibitors in Non-Small Cell Lung Cancer patients

Artificial Intelligence (AI)-driven biomarker discovery innovator Scailyte and the global single-cell genomics provider Geninus, today announce a strategic partnership to develop a patient stratification and prognostic platform for Non-Small Cell Lung Cancer (NSCLC).
Read More
Scailyte - Volv PR graphic

Scailyte and Volv Global announce strategic partnership to accelerate rare disease patient diagnosis

Two Artificial Intelligence (AI)-driven biomarker discovery companies Scailyte and Volv Global today announced a strategic partnership in developing a patient identification and diagnostic platform for rare diseases.
Read More
Making groundbreaking discoveries require collaborations and joint-ventures.